Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) subsidiaries applied for the renewal of its drugs under China's centralized drug procurement, according to a Shanghai bourse filing on Thursday.
More than 20 products were proposed for renewal as the previous procurement agreements are about to expire.